Q-omics provides the consensus-scored KRT19 profile across patient tissues and cancer cell-line models. KRT19 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, KRT19 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, KRT19 protein abundance shows 19,846 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight PAAD, KICH, and HNSC as cancer lineages where KRT19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT19 survival associations across molecular data types. KRT19 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT19 RNA expression–survival associations across cancer types. High KRT19 expression shows unfavorable associations in PAAD, KIRC, OV and KIRP, but favorable associations in ACC and SCLC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for KRT19 RNA expression.
This table summarizes KRT19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for KRT19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT19 shows lower tumor expression in KICH and KIRC and higher tumor expression in THCA, LUAD, LUSC and BRCA. The KICH box plot shows higher KRT19 RNA expression in normal versus tumor tissue (log2 FC = −6.628, t-test p < 0.001).
This table shows molecular features associated with KRT19 in patient tissues and cancer cell lines. In patient samples, KRT19 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
